Personensuche
Personensuche
Es wurde 1 Person gefunden.
Funktionen
-
Privatdozent/in, Innere Klinik (Tumorforschung)
Aktuelle Veranstaltungen
-
SoSe 2025
Vergangene Veranstaltungen (max. 10)
-
WiSe 2024
-
SoSe 2024
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Surgical treatment of multiple breast cancer brain metastases : Clinical characteristics and factors impacting postoperative survivalIn: Journal of Neuro-Oncology 2025 , in pressDOI (Open Access)
-
Applicability of a digital health application for cancer patients : A qualitative non-participation analysisIn: BMC Health Services Research , Jg. 24 2024, Nr. 1, 1187DOI (Open Access)
-
Comparison of Palliative Knowledge and Self-Efficacy Expectation of German Paramedics Between a Rural and an Urban Structured Emergency Medical Service AreaIn: Journal of Palliative Care (JPC) 2024 , in pressDOI (Open Access)
-
Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in EGFR-Mutated Lung Cancer with Unknown Mechanism of Acquired ResistanceIn: Journal of Nuclear Medicine (JNM) , Jg. 65 2024, Nr. 6, S. 851 – 855
-
Relevance of Patient-Reported Outcome Measures in Patients with Cancer : Detection of Underrated Psychological Distress of Palliative Care Patients in an Outpatient SettingIn: Palliative Medicine Reports , Jg. 5 2024, Nr. 1, S. 194 – 200DOI, Online Volltext (Open Access)
-
SOP – Schmerztherapie bei PalliativpatientenIn: Die Onkologie , Jg. 30 2024, Nr. Suppl. 2, S. 114 – 124
-
SOP – Subkutane Medikamentengabe und Infusionen in der erwachsenen PalliativmedizinIn: Die Onkologie , Jg. 30 2024, Nr. Suppl. 2, S. 98 – 105
-
The novel manualized RELIEVE-group treatment for burdened relatives of cancer patients : A feasibility studyIn: Frontiers in Psychology , Jg. 15 2024, 1492219DOI (Open Access)
-
Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world settingIn: Journal of Cancer Research and Clinical Oncology , Jg. 149 2023, Nr. 11, S. 9243 – 9252DOI (Open Access)
-
Location of Recurrences after Trimodality Treatment for Glioblastoma with Respect to the Delivered Radiation Dose Distribution and Its Influence on PrognosisIn: Cancers , Jg. 15 2023, Nr. 11, 2982DOI (Open Access)
-
SOP – Subkutane Medikamentengabe und Infusionen in der erwachsenen Palliativmedizin Version IIIn: Die Onkologie , Jg. 29 2023, Nr. 12, S. 1088 – 1096
-
The OUTREACH study: Oncologists of German university hospitals in rotation on a palliative care unit : Evaluation of attitude and competence in palliative care and hospiceIn: Journal of Cancer Research and Clinical Oncology , Jg. 149 2023, Nr. 7, S. 2929 – 2936DOI (Open Access)
-
PARPACT – Paramedic Palliative Care Test : Validierung eines Tests für palliatives Wissen und Selbstwirksamkeitserwartung bei Mitarbeiter*innen im RettungswesenIn: Der Schmerz , Jg. 36 2022, Nr. 5, S. 333 – 341DOI (Open Access)
-
Palliative care outpatients in a German comprehensive cancer center : identifying indicators for early and late referralIn: BMC Palliative Care , Jg. 21 2022, Nr. 1, 221DOI, Online Volltext (Open Access)
-
Prediction of Short and Long Survival after Surgery for Breast Cancer Brain MetastasesIn: Cancers , Jg. 14 2022, Nr. 6, 1437DOI, Online Volltext (Open Access)
-
Radiographic markers of breast cancer brain metastases : relation to clinical characteristics and postoperative outcomeIn: Acta Neurochirurgica , Jg. 164 2022, S. 439 – 449DOI (Open Access)
-
Time interval between the diagnosis of breast cancer and brain metastases impacts prognosis after metastasis surgeryIn: Journal of Neuro-Oncology , Jg. 159 2022, Nr. 1, S. 53 – 63DOI (Open Access)
-
A vaccine targeting mutant IDH1 in newly diagnosed gliomaIn: Nature , Jg. 592 2021, Nr. 7854, S. 463 – 468DOI (Open Access)
-
Changes in fatigue, barriers, and predictors towards physical activity in advanced cancer patients over a period of 12 months : A comparative studyIn: Supportive Care in Cancer , Jg. 29 2021, Nr. 9, S. 5127 – 5137DOI (Open Access)
-
Electrolyte and renal disorders in patients with newly diagnosed glioblastomaIn: Future Oncology , Jg. 17 2021, Nr. 34, S. 4711 – 4719DOI (Open Access)
-
HER2 Receptor Conversion Is a strong Survival Predictor in Patients with Breast Cancer Brain MetastasesIn: World Neurosurgery , Jg. 152 2021, S. e332 – e343
-
Fatigue, barriers to physical activity and predictors for motivation to exercise in advanced Cancer patientsIn: BMC Palliative Care , Jg. 19 2020, Nr. 1, S. 43DOI, Online Volltext (Open Access)
-
Improved survival in metastatic breast cancer : results from a 20-year study involving 1033 women treated at a single comprehensive cancer centerIn: Journal of Cancer Research and Clinical Oncology 2020DOI (Open Access)
-
Integration of palliative care into the comprehensive cancer center of Germany - Consultation hours and fellowship rotations of the specialized palliative careIn: TumorDiagnostik & Therapie , Jg. 40 2019, Nr. 5, S. 293 – 299
-
Knowledge and Self-Efficacy Assessment of Residents and Fellows Following Palliative Care Unit Rotation : A Pilot StudyIn: American Journal of Hospice & Palliative Medicine , Jg. 36 2019, Nr. 6, S. 492 – 499DOI, Online Volltext (Open Access)
-
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicityIn: Journal of the Peripheral Nervous System , Jg. 24 2019, Nr. 1, S. 111 – 119DOI (Open Access)
-
Treatment Outcome in Patients with Primary or Secondary Transformed Indolent B-Cell LymphomasIn: Oncology Research and Treatment , Jg. 42 2019, Nr. 11
-
11C-MET PET/MRI for detection of recurrent gliomaIn: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 45 2018, Nr. 4, S. 593 – 601
-
Integration von Palliativmedizin in onkologische Spitzenzentren Deutschlands – ambulante Sprechstunden und Rotationsprogramme der spezialisierten PalliativmedizinIn: Deutsche Medizinische Wochenschrift - DMW , Jg. 143 2018, Nr. 17, S. e139 – e145
-
MET Expression in Advanced Non–Small-Cell Lung Cancer : Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and ImmunotherapyIn: Clinical Lung Cancer , Jg. 19 2018, Nr. 4, S. e441 – e463
-
Patient-Reported-Outcome-Messung (PROM) psychosozialer Belastung und Symptome für ambulante Patienten unter kurativer oder palliativer Tumortherapie : eine retrospektive Analyse eines Comprehensive Cancer CenterIn: Der Onkologe , Jg. 24 2018, Nr. 1, S. 69 – 75
-
Predictors of outpatients’ request for palliative care service at a medical oncology clinic of a German comprehensive cancer centerIn: Supportive Care in Cancer , Jg. 26 2018, Nr. 10, S. 3641 – 3647
-
PriCoTTF : A phase I/II single-arm trial of tumor treating fields prior and concomitant with radiotherapy and temozolomide in newly diagnosed glioblastomaIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics , Jg. 194 2018, Nr. Suppl. 1, S. 73DOI (Open Access)
-
SOP – Schmerztherapie bei PalliativpatientenIn: Der Onkologe , Jg. 24 2018, Nr. Suppl. 1, S. 7 – 17
-
SOP – Subkutane Medikamentengabe und Infusionen in der erwachsenen PalliativmedizinIn: Der Onkologe , Jg. 24 2018, Nr. Suppl. 1, S. 60 – 67
-
High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung CancerIn: Journal of Thoracic Oncology , Jg. 12 2017, Nr. 1, S. 54 – 64DOI (Open Access)
-
Response assessment of bevacizumab therapy in GBM with integrated 11C-MET-PET/MRI : a feasibility studyIn: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 44 2017, Nr. 8, S. 1285 – 1295
-
SOP – Schmerztherapie bei PalliativpatientenIn: Der Onkologe , Jg. 23 2017, Nr. 7, S. 555 – 565
-
SOP – Subkutane Medikamentengabe und Infusionen in der erwachsenen PalliativmedizinIn: Der Onkologe , Jg. 23 2017, Nr. 8, S. 657 – 664
-
Integration der Palliativmedizin in die von der Deutschen Krebshilfe e. V. geförderten onkologischen SpitzenzentrenIn: Deutsche Medizinische Wochenschrift - DMW , Jg. 141 2016, Nr. 2, S. e16 – e23
-
Simultaneous 11C-methionine position emission tomography/magnetic resonance imaging of suspected primary brain tumorsIn: PLoS ONE , Jg. 11 2016, Nr. 12, S. e0167596DOI (Open Access)
-
Outcomes of Primary and Secondary Transformed B-Cell LymphomasIn: Blood , Jg. 126 2015, Nr. 23
-
Administration of Gemcitabine for Metastatic Adenocarcinoma during Pregnancy : A Case Report and Review of the LiteratureIn: American Journal of Perinatology Reports , Jg. 4 2014, Nr. 1, S. 017 – 022DOI (Open Access)
-
Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: : Secondary analysis of data from the CI-PeriNomS studyIn: Journal of the Peripheral Nervous System , Jg. 19 2014, Nr. 2, S. 127 – 135DOI (Open Access)
-
Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity : two sides of the same coinIn: Annals of Oncology , Jg. 25 2014, Nr. 1, S. 257 – 264
-
Brief S2k guidelines : merkel cell carcinomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 11 2013, Nr. Suppl. 3, S. 29 – 36
-
Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer CenterIn: European Journal of Cancer (EJC) , Jg. 49 2013, Nr. 15, S. 3076 – 3082
-
Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patientsIn: Breast Cancer Research and Treatment , Jg. 142 2013, Nr. 1, S. 81 – 88
-
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS)In: European Journal of Cancer (EJC) , Jg. 49 2013, Nr. 13, S. 2910 – 2918
-
The chemotherapy-induced peripheral neuropathy outcome measures standardization study : From consensus to the first validity and reliability findingsIn: Annals of Oncology , Jg. 24 2013, Nr. 2, S. 454 – 462
-
Visual field defect related to temozolomideIn: Neuro-Oncology , Jg. 15 2013, Nr. Suppl. 3, S. 116
-
Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octrotateIn: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 39 2012, Nr. Suppl. 2, S. 233
-
VVTZ-Tumorprofil - First results of a preemptive biomarker profiling program in relation to personalized clinical drug development at a large German Comprehensive Cancer CenterIn: Onkologie , Jg. 35 2012, Nr. Suppl. 6, S. 204 – 204
-
A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatmentIn: International Journal of Clinical Pharmacology and Therapeutics , Jg. 49 2011, Nr. 1, S. 96 – 98
-
Long survival of primary diffuse leptomeningeal gliomatosis following radiotherapy and temozolomide : case report and literature reviewIn: European Journal of Medical Research , Jg. 16 2011, Nr. 9, S. 415 – 419DOI (Open Access)
-
Multivisceral systemic metastases from an intracranial anaplastic meningioma : A case report and review of literatureIn: Clinical Neurology and Neurosurgery , Jg. 113 2011, Nr. 7, S. 592 – 595
-
Treatable Bortezomib-related peripheral neuropathy in multiple myelomaIn: Journal of the Peripheral Nervous System , Jg. 16 2011, Nr. Suppl. 3, S. 68
-
Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin's lymphomaIn: Journal of Cancer Research and Clinical Oncology , Jg. 135 2009, Nr. 3, S. 459 – 466
-
Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myelomaIn: European Journal of Haematology , Jg. 74 2005, Nr. 1, S. 40 – 46
-
Langzeitergebnisse nach hypofraktionierter ablativer Präzisionsbestrahlung bei Patienten mit multiplen cerebralen MetastasenIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics , Jg. 199 2023, Nr. Suppl. 1, S. S124DOI (Open Access)
-
Image-guided ablative Radiotherapy for Patients with multiple cerebral Metastases using Precision helical IrradiationIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics , Jg. 197 2021, Nr. Suppl. 1, S. 183
-
Influence of external and self-assessment in symptom burden of cancer patients in a palliative care outpatient clinic of a Comprehensive Cancer Center
Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,In: Oncology Research and Treatment , Jg. 44 2021, Nr. Supplement 2, S. 92DOI (Open Access) -
Systemic inflammatory response parameters as prognostic markers in patients with recurrent or metastatic head and neck cancer treated with immunotherapy
Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,In: Oncology Research and Treatment , Jg. 44 2021, Nr. Supplement 2, S. 58DOI (Open Access) -
Palliative knowledge and self-efficacy expectation of residents before and after palliative care unit rotation - A national study project
Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,In: Oncology Research and Treatment , Jg. 43 2020, Nr. Suppl. 4, S. 210DOI (Open Access) -
Patients with metastatic EGFR-mutated non-small cell lung cancer (NSCLC) show highly favorable outcomes with treatment sequences provided at a comprehensive cancer center
Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,In: Oncology Research and Treatment , Jg. 43 2020, Nr. Suppl. 4, S. 137DOI (Open Access) -
Barriers and motivation of physical activitiy (PA) in patients with cancer related fatigue (CRF)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 11. - 14. Oktober 2019, Berlin, Germany,In: Oncology Research and Treatment , Jg. 42 2019, Nr. Supplement 4: Abstracts, S. 165DOI (Open Access) -
A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group evaluating a mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomasIn: Neuro-Oncology , Jg. 20 2018, Nr. suppl_3, S. iii226 – iii227DOI (Open Access)
-
A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas : A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16)In: Journal of Clinical Oncology (JCO) , Jg. 36 2018, Nr. Suppl. 15, S. 2001DOI (Open Access)
-
ACTR-49. PriCoTTF: A PHASE I/II TRIAL OF TUMOR TREATING FIELDS PRIOR AND CONCOMITANT TO RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA
23rd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology November 15 – 18, 2018 New Orleans, USA,In: Neuro-Oncology , Jg. 20 2018, Nr. suppl_6, S. vi22 – vi23DOI (Open Access) -
ATIM-33. NOA-16: A FIRST-IN-MAN MULTICENTER PHASE I CLINICAL TRIAL OF THE GERMAN NEUROONCOLOGY WORKING GROUP EVALUATING A MUTATION-SPECIFIC PEPTIDE VACCINE TARGETING IDH1R132H IN PATIENTS WITH NEWLY DIAGNOSED MALIGNANT ASTROCYTOMAS
23rd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology November 15 – 18, 2018 New Orleans, USA,In: Neuro-Oncology , Jg. 20 2018, Nr. suppl_6, S. vi8 – vi9DOI (Open Access) -
PriCoTTF : a phase I/II trial of Tumor Treating Fields prior and concomitant to radiotherapy in newly diagnosed glioblastomaIn: Neuro-Oncology , Jg. 20 2018, Nr. suppl_3, S. iii243 – iii243DOI (Open Access)
-
Palliative Care at Comprehensive Cancer Center : A comparative look at integration in Germany
Krebsmedizin heute: präventiv, personalisiert, präzise und partizipativ ; 32. Deutscher Krebskongress ; 24.-27. Februar 2016, Berlin,In: Oncology Research and Treatment , Jg. 39 2016, Nr. Suppl. 1, S. 129 -
Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patientsIn: Oncology Research and Treatment , Jg. 37 2014, Nr. Suppl. 1: 31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie Berlin, 19.-22. Februar 2014: Abstracts, S. 19DOI (Open Access)
-
WTZ-Tumorprofil-A preemptive biomarker profiling program in relation to personalized clinical drug development at a large German Comprehensive Cancer Center : Two years experience
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin, Germany,In: Oncology Research and Treatment , Jg. 37 2014, Nr. Suppl. 1, S. 2 – 3 -
Physician-assessed and petient-reported outcome measuresin chemotherapy-induced sensory peripheral neurotoxicity : two sides of the same coin
Meeting of the Peripheral Nerve Society, June 29–July 3, 2013, Saint–Malo, France,In: Journal of the Peripheral Nervous System , Jg. 18 2013, Nr. S2, S. 3 – 4 -
Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastastic breast cancer patients
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Oncology Research and Treatment , Jg. 36 2013, Nr. Suppl. 7, S. 157 -
Provider perceptions of clinical neuropathy examination usefulness
Meeting of the Peripheral Nerve Society, June 29–July 3, 2013, Saint–Malo, France,In: Journal of the Peripheral Nervous System , Jg. 18 2013, Nr. 2, S. 42 – 43 -
An investigator-initiated monocentric phase I dose escalation trial of temsirolimus and irinotecan (TEMIR) in patients with relapsing glioblastoma multiforme (reGBM)
48th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1-5, 2012, Chicago, Ill., USA,In: Journal of Clinical Oncology (JCO) , Jg. 30 2012, Nr. 15, Suppl., 2086 -
Impact of EGFR mutation status on clinical benefit from BIBW 2992 in patients (PTS) with advanced non-small lung cancer (NSCLC) progressing after chemotherapy (CTX) and erlotinib (E) or gefitinib (G) : a single center experience
37th ESMO Congress, 28 September - 2 October 2012, Vienna, Austria,In: Annals of Oncology , Jg. 23 2012, Nr. Suppl. 9, S. 437 – 438 -
Efficacy of immunotherapy (IO) and subsequent systemic treatment after failure of IO in patients with recurrent or metastatic head and neck cancer in a real-world setting
ESMO Congress 2021, 16 – 21 September 2021, Virtual,In: Annals of Oncology , Jg. 32 2021, Nr. Suppl. 5, S. S812DOI (Open Access) -
Formation of multiple pneumatoceles during anti-angiogenic treatment for metastatic colorectal cancer
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 10.–14. Oktober 2014, Hamburg, Germany,In: Oncology Research and Treatment , Jg. 37 2014, Nr. Suppl. 5, S. 84 – 85 -
Register trial of sorafenib (S) for patients (pts) with metastatic uveal melanoma (metUvMel)
EORTC – NCI – ASCO Annual Meeting on ‘Molecular Markers in Cancer’, 27-29 October 2011, Brussels, Belgium,In: European Journal of Cancer (EJC) , Jg. 47 2011, Nr. Suppl. 4, S. S30